Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease

Fig. 3

a Comparison of serum BAFF levels in all subjects. b Comparison of serum BAFF levels between NASH patients seropositive and seronegative for ANAs. c Comparison of serum BAFF levels between CLD-C patients seropositive and seronegative for ANAs. The boxes represent the values within 25th and 75th percentiles. The horizontal bars represent the medians. BAFF B-lymphocyte activating factor, NASH nonalcoholic steatohepatitis, NHC normal healthy control, CLD-C HCV-related chronic liver disease

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us